Northwire Canada EditionTuesday, July 14, 2026
Sign inSubscribe
Northwire
⌕
WDO 26.04 −0.9% FVI 11.84 −1.6% OM 1.75 −1.7% ETG 2.99 +0.0% ARTG 31.47 −4.6% LUC 0.163 +1.6% AFM 1.38 +0.0% IMG 20.95 −3.5% CPAU 0.150 +3.5% MMX 0.075 +7.1% IE 12.47 −2.4% SASK 1.09 −1.8% MOG 0.390 +2.6% XIM 0.070 −6.7% S 0.110 −29.0% OMI 0.300 −4.8% WDO 26.04 −0.9% FVI 11.84 −1.6% OM 1.75 −1.7% ETG 2.99 +0.0% ARTG 31.47 −4.6% LUC 0.163 +1.6% AFM 1.38 +0.0% IMG 20.95 −3.5% CPAU 0.150 +3.5% MMX 0.075 +7.1% IE 12.47 −2.4% SASK 1.09 −1.8% MOG 0.390 +2.6% XIM 0.070 −6.7% S 0.110 −29.0% OMI 0.300 −4.8%
M&A / Property

Optimi Health's Psilocybin Capsules Selected for Medibank Insurance Program

By The Northwire Desk — AI Analysis Oct 06, 2025 · 07:01 OPTI · 0.395 Optimi Health Corp.
OPTI · Price

Executive Summary

  • Optimi Health’s 5 mg naturally‑derived psilocybin capsules have been selected for inclusion in Medibank’s AUD $10 million insurance‑backed psychotherapy program for Treatment‑Resistant Depression (TRD).
  • The program is part of Medibank’s broader AUD $50 million, five‑year initiative to expand access to novel mental‑health therapies, including both psilocybin and MDMA.
  • Optimi’s exclusive Australian distributor, Mind Medicine Australia, will supply the capsules through Emyria Limited’s Empax Centre in Perth.

Key Details

  • Program Funding: AUD $10 million allocated by Medibank for reimbursement of psilocybin‑assisted therapy for TRD patients.
  • Broader Initiative: Medibank has committed AUD $50 million over five years to mental‑health innovation, prevention, and access.
  • Distribution Chain:
  • Optimi Health (manufacturer) → Mind Medicine Australia (exclusive Australian distributor) → Empax Centre (EMyria Limited) → Medibank insured patients.
  • Product Availability: Optimi’s psilocybin capsules were first made available in Australia on September 3, 2025 under the Authorized Prescriber Scheme.
  • CEO Quote: Dane Stevens highlighted that inclusion “reflects the growing role of standardized psychedelic medicines in insured mental health care” and marks a step toward integration into insurance‑backed regulated care.
  • Contact Information for Access: [email protected] (general); [email protected] (Australian prescribers).

Notable Quotes

“The inclusion of our psilocybin capsules in Medibank's insurance‑backed program for treatment‑resistant depression reflects the growing role of standardized psychedelic medicines in insured mental health care.” – Dane Stevens, CEO, Optimi Health Corp.

Read the original news release →

More from Optimi Health Corp.

Jun 29, 2026 · 09:00

Optimi Health Completes Psilocybin Export to Australia for Patients With Treatment-Resistant Depression

Production / Operations Jun 16, 2026 · 08:30

Vertically integrated GMP psychedelic manufacturer scaling clinical supply, but revenue remains negligible and execution is incremental.

Production / Operations Jun 10, 2026 · 09:15

Optimi Health Completes First Export of Psilocybin to the United Kingdom for Phase 2 Clinical Trial

Production / Operations Jun 08, 2026 · 08:00

Psychedelic GMP manufacturer advances ibogaine development amid US policy tailwinds, but commercial revenue remains negligible.

Regulatory Jun 02, 2026 · 07:30

Optimi Health Completes Commercial Psilocybin Production to Address Treatment-Resistant Depression in Australia

Production / Operations May 29, 2026 · 08:30

Australia widens insurance-backed psychedelic therapy access — Optimi’s existing supply chain gains yet another tailwind, but market still awaits proof-of-revenue.

Regulatory